Preclinical studies in our lab corroborate this hypothesis as anti-IL-2Rα MAb administration during temozolomide (TMZ) induced lymphopenia depletes TRegs while sparing activated effectors to enhance anti-tumor efficacy in an established model of murine tumorigenesis [33]. The gene discussed is IL2RA; the disease is lymphopenia.